Core Viewpoint - The company, Aoxiang Pharmaceutical (603229.SH), announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the oncology sector [1] Group 1: Product Information - Imatinib Mesylate Tablets are the world's first targeted molecular therapy for cancer, specifically indicated for patients with chronic myeloid leukemia (CML) in acute or accelerated phases, or those who have failed alpha-interferon treatment, as well as for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1] - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively suppresses the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function, thereby inhibiting abnormal white blood cell proliferation [1] - Imatinib also binds to the active site of tyrosine kinase, blocking its activity [1]